PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Francesco Cognetti(National Cancer Institute), Sandro Barni, Angelo Fedele Scinto, Rossana Berardi(Marche Polytechnic University), Giuseppe Naso(Policlinico Umberto I), Daniele Generali(University of Trieste), Giulia Bianchi, Agnese Fabbri(Ospedale di Belcolle), Alberto Zambelli, Daniela Terribile(Agostino Gemelli University Polyclinic), Emilia Marrazzo(Fondazione Humanitas per la Ricerca), Teresa Gamucci, Alessandra Fabi(Agostino Gemelli University Polyclinic), Giovanna Catania(Istituti di Ricovero e Cura a Carattere Scientifico), Marco Colleoni(European Institute of Oncology), Domenico Angelucci(Istituto Ortopedico Gaetano Pini), Giuseppe Tonini(Campus Bio Medico University Hospital), Leonardo Vigna(Azienda Ospedaliera San Camillo-Forlanini), Mario Giuliano(Regione Campania), Donatella Santini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanni Scognamiglio(Ospedale Valduce), Alessia Rognone(IRCCS Ospedale San Raffaele), Corrado Tinterri(Humanitas University), Riccardo Masetti(Agostino Gemelli University Polyclinic), Lucia Vassalli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Francesco Scanzi(MultiMedica), Graziella Pinotti(Ospedale di Circolo e Fondazione Macchi), Paola Scavina(Azienda Ospedaliera San Giovanni Addolorata), Daniela Franco(Ospedale Regina Margherita), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico)
npj Breast Cancer
May 5, 2021
10.1038/s41523-021-00246-4
Cited by 29

Related Papers

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k